Evaluation of claims, medical records, and self-report for measuring fecal occult blood testing among medicare enrollees in fee for service
- PMID: 18381471
- DOI: 10.1158/1055-9965.EPI-07-2620
Evaluation of claims, medical records, and self-report for measuring fecal occult blood testing among medicare enrollees in fee for service
Abstract
Background: There is no agreement on the best data source for measuring colorectal cancer (CRC) screening. Medicare claims have been used to measure CRC testing but the validity of using claims to measure fecal occult blood tests (FOBT) has not been established.
Methods: We compared ascertainment of FOBT among three data sources: self-reports, Medicare claims, and medical records. Data were collected on FOBT use during the study window (1/1/1998 - 12/31/2002). Our study was conducted with North Carolina Medicare enrollees (N = 561) who had previously responded to a telephone survey on CRC tests. FOBT information was abstracted from respondents' physician office medical records and compared with self-reported FOBT use and Medicare claims for FOBT. Data sources were assessed for accuracy and completeness of FOBT reporting using sensitivity, specificity, positive predictive value, negative predictive value, and agreement.
Results: Reporting of FOBT use in the prior year in medical records and Medicare claims agreed 82% of the time [95% confidence interval (95% CI), 79-85%]. FOBT 1-year use rates from self-report agreed with test use found in medical records 70% of the time (95% CI, 66-74%). The lowest agreement was between self-reported 1-year FOBT use and Medicare claims, which agreed 67% of the time (95% CI, 63-71%).
Conclusions: No data source could be established as providing complete and valid information about FOBT use among Medicare enrollees, showing the difficulty of ascertaining test use rates for noninvasive, low-cost procedures conducted in multiple settings. Caution should be used when attempting to measure FOBT use with self-report, Medicare claims, or medical records.
Similar articles
-
Data sources for measuring colorectal endoscopy use among Medicare enrollees.Cancer Epidemiol Biomarkers Prev. 2007 Oct;16(10):2118-27. doi: 10.1158/1055-9965.EPI-07-0123. Cancer Epidemiol Biomarkers Prev. 2007. PMID: 17932360
-
Validation of self-reported history of colorectal cancer screening.Can Fam Physician. 2007 Jul;53(7):1192-7. Can Fam Physician. 2007. PMID: 17872816 Free PMC article.
-
Is the type of Medicare insurance associated with colorectal cancer screening prevalence and selection of screening strategy?Med Care. 2008 Sep;46(9 Suppl 1):S84-90. doi: 10.1097/MLR.0b013e31817fdf80. Med Care. 2008. PMID: 18725838
-
[Features of colorectal cancer with fecal-occult-blood tests--comparison with colorectal cancer with no screening].Gan To Kagaku Ryoho. 1998 Aug;25(10):1514-8. Gan To Kagaku Ryoho. 1998. PMID: 9725042 Review. Japanese.
-
Noninvasive testing for colorectal cancer: a review.Am J Gastroenterol. 2005 Jun;100(6):1393-403. doi: 10.1111/j.1572-0241.2005.41427.x. Am J Gastroenterol. 2005. PMID: 15929776 Review.
Cited by
-
Correlates of self-reported colorectal cancer screening accuracy in a multi-specialty medical group practice.Open J Epidemiol. 2013 Feb;3(1):20-24. doi: 10.4236/ojepi.2013.31004. Open J Epidemiol. 2013. PMID: 24027657 Free PMC article.
-
Using the SEER-Medicare Data to Assess Incident Chronic Myeloid Leukemia and Bladder Cancer Cases Missed by Cancer Registries.J Natl Cancer Inst Monogr. 2020 May 1;2020(55):31-38. doi: 10.1093/jncimonographs/lgz033. J Natl Cancer Inst Monogr. 2020. PMID: 32412074 Free PMC article.
-
Screening flexible sigmoidoscopy versus colonoscopy for reduction of colorectal cancer mortality.Int J Colorectal Dis. 2019 Jul;34(7):1273-1281. doi: 10.1007/s00384-019-03300-7. Epub 2019 May 31. Int J Colorectal Dis. 2019. PMID: 31152198 Free PMC article.
-
Screening for colorectal cancer in a safety-net health care system: access to care is critical and has implications for screening policy.Cancer Epidemiol Biomarkers Prev. 2009 Sep;18(9):2373-9. doi: 10.1158/1055-9965.EPI-09-0344. Cancer Epidemiol Biomarkers Prev. 2009. PMID: 19745221 Free PMC article.
-
Evaluating Lung Cancer Screening Uptake, Outcomes, and Costs in the United States: Challenges With Existing Data and Recommendations for Improvement.J Natl Cancer Inst. 2019 Apr 1;111(4):342-349. doi: 10.1093/jnci/djy228. J Natl Cancer Inst. 2019. PMID: 30698792 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical